{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:33:45Z","timestamp":1794555225018,"version":"4.9.1"},"reference-count":94,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Retinoids have numerous applications in inflammatory, dyskeratotic, and oncohematology diseases. Retinoids have now reached the fourth generation, progressively reducing toxicity whilst increasing their efficacy. Trifarotene is a new fourth-generation retinoid with a selective action on RAR-\u03b3. In this review, we reported the trials\u2014both concluded and in progress\u2014including the use of trifarotene in dermatological diseases. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) from 2012 to today and reference lists of respective articles. Only articles published in English language were included. Randomized trials evaluating trifarotene tolerability, safety, and efficacy in congenital ichthyosis and acne have demonstrated great results and mild side effects, leading to the approval by the FDA of trifarotene for the treatment of lamellar ichthyosis in 2014, and of acne vulgaris in October 2019. No high-quality randomized clinical trials have evaluated the treatment of primary cutaneous lymphomas with trifarotene. Finally, we are hypothesizing future perspectives in the treatment of non-melanoma skin cancers, fungal infections, photoaging, and hand-foot skin reactions with trifarotene.<\/jats:p>","DOI":"10.3390\/biomedicines9030237","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T09:47:20Z","timestamp":1614332840000},"page":"237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Trifarotene: A Current Review and Perspectives in Dermatology"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-7882","authenticated-orcid":false,"given":"Terenzio","family":"Cosio","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-8540","authenticated-orcid":false,"given":"Monia","family":"Di Prete","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-2670","authenticated-orcid":false,"given":"Roberta","family":"Gaziano","sequence":"additional","affiliation":[{"name":"Microbiology Section, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Lanna","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-5854","authenticated-orcid":false,"given":"Augusto","family":"Orlandi","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Di Francesco","sequence":"additional","affiliation":[{"name":"Microbiology Section, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campione","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"ref_1","unstructured":"(1982). Nomenclature of retinoids. Recommendations. Eur. J. Biochem., 129, 1\u20135."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jphs.2020.06.003","article-title":"Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections","volume":"144","author":"Campione","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1126\/science.1136244","article-title":"A Membrane Receptor for Retinol Binding Protein Mediates Cellular Uptake of Vitamin A","volume":"315","author":"Kawaguchi","year":"2007","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0960-0760(95)00092-E","article-title":"The cellular retinoic acid binding proteins","volume":"53","author":"Donovan","year":"1995","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/nrd1551","article-title":"Principles for modulation of the nuclear receptor superfamily","volume":"3","author":"Gronemeyer","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1073\/pnas.90.1.30","article-title":"Retinoic acid receptors and retinoid X receptors: Interactions with endogenous retinoic acids","volume":"90","author":"Allenby","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jsbmb.2005.05.005","article-title":"A robust characterization of retinoic acid response elements based on a comparison of sites in three species","volume":"96","author":"Balmer","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1096\/fasebj.10.9.8801176","article-title":"A decade of molecular biology of retinoic acid receptors","volume":"10","author":"Chambon","year":"1996","journal-title":"FASEB J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.mce.2011.03.025","article-title":"Nuclear retinoic acid receptors: Conductors of the retinoic acid symphony during development","volume":"348","author":"Samarut","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/sj.onc.1204329","article-title":"Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription","volume":"20","author":"Dilworth","year":"2001","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1128\/MCB.23.8.2844-2858.2003","article-title":"Isotype-restricted corepressor recruitment: A constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression","volume":"23","author":"Farboud","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/me.2002-0340","article-title":"Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand","volume":"17","author":"Hauksdottir","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Asson-Batres, M.A., and Rochette-Egly, C. (2014). The Biochemistry of Retinoic Acid Receptors I: Structure, Activation, and Function at the Molecular Level, Springer. Subcellular Biochemistry.","DOI":"10.1007\/978-94-017-9050-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1074\/jbc.M808815200","article-title":"SUG-1 Plays Proteolytic and Non-proteolytic Roles in the Control of Retinoic Acid Target Genes via Its Interaction with SRC","volume":"284","author":"Ferry","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1093\/emboj\/cdf374","article-title":"Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation","volume":"21","author":"Bauer","year":"2002","journal-title":"EMBO J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","article-title":"Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects","volume":"28","author":"Khalil","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.102.1.113","article-title":"Retinoic acid receptor expression in human skin keratinocytes and dermal fibroblasts in vitro","volume":"102","author":"Redfern","year":"1992","journal-title":"J. Cell Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bmcl.2018.04.036","article-title":"Structure-based design of Trifarotene (CD5789), a potent and selective RAR\u03b3 agonist for the treatment of acne","volume":"28","author":"Thoreau","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_19","first-page":"442","article-title":"Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-\u03b3 agonist trifarotene","volume":"179","author":"Aubert","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_20","unstructured":"Food and Drug Administration (2020, August 06). Novel Drug Approvals for 2019, Available online: http:\/\/www.fda.gov."},{"key":"ref_21","unstructured":"Galderma (2020, August 06). Aklief\u00ae (Trifarotene): US Prescribing Information. Available online: http:\/\/www.galderma.com\/."},{"key":"ref_22","first-page":"s51","article-title":"Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments","volume":"17","author":"Chien","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bmcl.2008.11.040","article-title":"Novel non-carboxylic acid retinoids: 1,2,4-Oxadiazol-5-one derivatives","volume":"19","author":"Charton","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm00026a006","article-title":"Synthesis, Structure-Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes","volume":"38","author":"Charpentier","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol. Cell. Proteom."},{"key":"ref_26","unstructured":"(2020, August 06). Maynepharma. Available online: https:\/\/www.maynepharma.com\/innovation\/novel-pipeline\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jcph.1566","article-title":"Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RAR\u03b3-Selective Topical Retinoid","volume":"60","author":"Ms","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_28","unstructured":"Drugs.com (2020, August 06). Gleolan (Aminolevulinic Acid) Drug Interactions from Drugs.com; c1996\u20132018 [Updated: 20 November 2018]. Available online: https:\/\/www.drugs.com\/mtm\/gleolan.html."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1542\/pir.34.11.479","article-title":"Acne and Its Management","volume":"34","author":"Basak","year":"2013","journal-title":"Pediatr. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/archderm.134.4.454","article-title":"Acne vulgaris and the quality of life of adult dermatology patients","volume":"134","author":"Lasek","year":"1998","journal-title":"Arch. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2133.1997.tb03787.x","article-title":"The effectiveness of acne treatment: An assessment by patients of the outcome of therapy","volume":"137","author":"Newton","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European Evidence-based (S3) Guidelines for the Treatment of Acne","volume":"26","author":"Nast","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.0926-9959.2001.00006.x","article-title":"Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne","volume":"15","author":"Czernielewski","year":"2001","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2133.1998.1390s2003.x","article-title":"Pharmacology of adapalene","volume":"139","author":"Michel","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","article-title":"Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne","volume":"80","author":"Tan","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","first-page":"166","article-title":"Long-term safety and efficacy of trifarotene 50 \u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne","volume":"34","author":"Fowler","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s13555-020-00417-4","article-title":"Subject Satisfaction with Trifarotene 50 \u03bcg\/g Cream in the Treatment of Facial and Truncal Acne Vulgaris: A Case Series","volume":"10","author":"Johnson","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lee, Y.B., Byun, E.J., and Kim, H.S. (2019). Potential Role of the Microbiome in Acne: A Comprehensive Review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070987"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jid.2018.09.023","article-title":"Skin Ecology during Sebaceous Drought\u2014How Skin Microbes Respond to Isotretinoin","volume":"139","author":"McCoy","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.0022-202X.2005.23791.x","article-title":"Retinoic Acid and its 4-Oxo Metabolites are Functionally Active in Human Skin Cells In Vitro","volume":"125","author":"Baron","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI115990","article-title":"Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro","volume":"4","author":"Duell","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbalip.2011.08.017","article-title":"Endogenous retinoids in the hair follicle and sebaceous gland","volume":"1821","author":"Everts","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_44","first-page":"1463","article-title":"Cellular localization of retinoic acid receptor-gamma expression in normal and neoplastic skin","volume":"140","author":"Finzi","year":"1992","journal-title":"Am. J. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/sj.jid.5700944","article-title":"PPAR and LXR Activators Regulate ABCA12 Expression in Human Keratinocytes","volume":"128","author":"Jiang","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2230.2003.01318.x","article-title":"Type I lamellar ichthyosis improved by tazarotene 0.1% gel","volume":"28","author":"Marulli","year":"2003","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/000155501750376221","article-title":"Phenotypic\/Genotypic Correlations in Patients with Epidermolytic Hyperkeratosis and the Effects of Retinoid Therapy on Keratin Expression","volume":"81","author":"Virtanen","year":"2001","journal-title":"Acta Derm. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2133.1989.tb01432.x","article-title":"Acitretin monotherapy in Darier\u2019s disease","volume":"121","author":"Happle","year":"1989","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jamadermatol.2017.0202","article-title":"Expanding the Genotypic Spectrum of Bathing Suit Ichthyosis","volume":"153","author":"Marukian","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Burns, T., Breathnach, S., Cox, N., and Griffiths, C. (2004). Cutaneous lymphomas and lymphocytic infiltrates. Rook\u2019s Textbook of Dermatology, Blackwell Science Ltd.. [7th ed.].","DOI":"10.1002\/9780470750520"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and Sezary syndrome","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","first-page":"1372","article-title":"Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II","volume":"89","author":"Paulli","year":"2004","journal-title":"Haematologica"},{"key":"ref_55","first-page":"475","article-title":"Environmental factors and allergic diseases","volume":"19","author":"Jenerowicz","year":"2012","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5114\/aoms.2011.20600","article-title":"Primary breast lymphoma\u2014A review of the literature and report of three cases","volume":"1","author":"Joks","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1994.12.6.1185","article-title":"Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study","volume":"12","author":"Cheng","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/cimm.1993.1003","article-title":"Upregulation by Retinoic Acid of Interleukin-2-Receptor mRNA in Human T Lymphocytes","volume":"146","author":"Sidell","year":"1993","journal-title":"Cell. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR rexinoids: Modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/dth.12087","article-title":"Topical and oral bexarotene","volume":"26","author":"Schadt","year":"2013","journal-title":"Dermatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2019.00260","article-title":"Skin Directed Therapy in Cutaneous T-Cell Lymphoma","volume":"9","author":"Tarabadkar","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1203475415626686","article-title":"Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma","volume":"20","author":"Roberge","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_63","unstructured":"ClinicalTrials.gov (2020, August 06). Bethesda (MD): National Library of Medicine (US). Identifier NCT03738800, A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents with Lamellar Ichthyosis; 2019 May 1 [about 4 Screens]. 29 February, Available online: https:\/\/ichgcp.net\/clinical-trials-registry\/NCT03738800\/."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1529-8019.2006.00088.x","article-title":"Skin cancer chemoprevention with systemic retinoids: An adjunct in the management of selected high-risk patients","volume":"19","author":"Campbell","year":"2006","journal-title":"Dermatol. Ther."},{"key":"ref_65","first-page":"33","article-title":"Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells","volume":"605","author":"Lotan","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/14656566.9.8.1363","article-title":"Systemic retinoids in chemoprevention of non-melanoma skin cancer","volume":"9","author":"Lens","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-8-27","article-title":"Identification of the B-Raf\/Mek\/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion","volume":"8","author":"Cheepala","year":"2009","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000056370","article-title":"Cutaneous Vitamins A and E in the Context of Ultraviolet- or Chemically-Induced Oxidative Stress","volume":"14","author":"Sorg","year":"2001","journal-title":"Skin Pharmacol. Appl. Skin Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(82)91393-9","article-title":"Etretinate in treatment of actinic keratosis. A double-blind crossover study","volume":"319","author":"Moriarty","year":"1982","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study","volume":"13","author":"Bavinck","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF01965758","article-title":"Retinoic acid: Topical treatment of senile or actinic keratoses and basal cell carcinomas","volume":"1","author":"Bollag","year":"1970","journal-title":"Agents Actions"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.22414.x","article-title":"Evidence of Increased Apoptosis and Reduced Proliferation in Basal Cell Carcinomas Treated with Tazarotene","volume":"122","author":"Orlandi","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2133.2004.06044.x","article-title":"Topical treatment of basal cell carcinoma with tazarotene: A clinicopathological study on a large series of cases","volume":"151","author":"Bianchi","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/S0190-9622(03)01587-1","article-title":"Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: A nested cohort study","volume":"49","author":"Nijsten","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamadermatol.2019.1937","article-title":"Association of Vitamin A Intake With Cutaneous Squamous Cell Carcinoma Risk in the United States","volume":"155","author":"Kim","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cosio, T., Di Prete, M., and Campione, E. (2020). Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma. Biomedicines, 8.","DOI":"10.3390\/biomedicines8060156"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/03007995.2016.1174678","article-title":"Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: Efficacy and tolerability on actinic keratosis. A proof of concept study","volume":"32","author":"Babino","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.leu.2402899","article-title":"Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen","volume":"17","author":"Girmenia","year":"2003","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2147\/DDDT.S69946","article-title":"Tazarotene as alternative topical treatment for onychomycosis","volume":"9","author":"Campione","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2147\/DDDT.S93985","article-title":"Fungistatic activity of all-trans retinoic acid against Aspergillus fumigatus and Candida albicans","volume":"10","author":"Campione","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Lei, G.-S., Zhang, C., Shao, S., Jung, H.-W., Durant, P.J., and Lee, C.-H. (2013). All-Trans Retinoic Acid in Combination with Primaquine Clears Pneumocystis Infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053479"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00430-014-0351-4","article-title":"Modulatory role of vitamin A on the Candida albicans-induced immune response in human monocytes","volume":"203","author":"Klassert","year":"2014","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Campione, E., Gaziano, R., Doldo, E., Marino, D., Falconi, M., Iacovelli, F., Tagliaferri, D., Pacello, L., Bianchi, L., and Lanna, C. (2020). Antifungal Effect of All-trans Retinoic Acid against Aspergillus fumigatus In Vitro and in a Pulmonary Aspergillosis In Vivo Model. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.01874-20"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: Treatment and prevention of recurrence","volume":"80","author":"Lipner","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: Pathogenesis, Diagnosis, and Management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1476-5381.2012.02031.x","article-title":"Retinoids: Novel immunomodulators and tumour-suppressive agents?","volume":"167","author":"Marasco","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0190-9622(86)70242-9","article-title":"Topical tretinoin for photoaged skin","volume":"15 (Pt 2)","author":"Kligman","year":"1986","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3892\/mmr.2017.7336","article-title":"Retinoic acid ameliorates photoaged skin through RAR-mediated pathway in mice","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Rusu, A., Tanase, C., Pascu, G.-A., and Todoran, N. (2020). Recent Advances Regarding the Therapeutic Potential of Adapalene. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090217"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jocd.13463","article-title":"Clinical efficacy and reflectance confocal microscopy monitoring in moderate-severe skin aging treated with a polyvinyl gel containing retinoic and glycolic acid: An assessor-blinded 1-month study proof-of-concept trial","volume":"20","author":"Campione","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1592\/phco.27.8.1125","article-title":"Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer","volume":"27","author":"Grandinetti","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_93","unstructured":"ClinicalTrials.gov (2020, September 03). Bethesda (MD): National Library of Medicine (US). Identifier NCT00667589, Four-Arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-Foot Skin Reaction Related to the Use of Multi-Targeted Tyrosine Kinase Inhibitor Sorafenib. 5 June 2013; [about 4 Screens]. 29 February, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00667589?cond=hand-foot+skin+reaction&draw=2&rank=5."},{"key":"ref_94","unstructured":"ClinicalTrials.gov (2020, September 03). Bethesda (MD): National Library of Medicine (US). Identifier NCT04071756, A Phase II Randomized Double-Blind Trial of Topical Tazarotene 0.1% Gel Versus Placebo Gel for the Prevention of Regoraf-Enib-Induced Hand-Foot-Skin Reaction; 12 December 2019; [about 4 Screens]. 29 February, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04071756?term=tazarotene&draw=2&rank=1."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/3\/237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:29:26Z","timestamp":1760160566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/3\/237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":94,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["biomedicines9030237"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9030237","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}